Tiziana Life Sciences Ltd (0RP.F)
Tiziana Life Sciences Ltd
14/15 Conduit Street
London W1S 2XJ
United Kingdom
https://www.tizianalifesciences.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 9
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Gabriele Marco Antonio Cerrone M.B.A. | Founder, Executive Chairman & Interim CEO | 762.2k | N/D | 1972 |
| Ms. Keeren Shah | Chief Financial Officer | N/D | N/D | 1976 |
| Dr. Matthew W. Davis M.D., R.Ph. | COO & Chief Medical Officer | N/D | N/D | N/D |
| Dr. William A. Clementi Ph.D., Pharm.D. | Chief Development Officer | N/D | N/D | N/D |
| Dr. Napoleone Ferrara M.D. | Member of Scientific Advisory Board | N/D | N/D | 1958 |
Descripción
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
Gestión corporativa
La calificación ISS Governance QuickScore de Tiziana Life Sciences Ltd a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
